Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/223521
Title: The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS)
Author: A.j. Hendricks, Linda
C.j. Verbeek, Katja
H.m. Schuurs-hoeijmakers, Janneke
M. De Jong, Mirjam
P. Links, Thera
Brems, Hilde
Aerden, Mio
Brunet, Joan
Lleuger-pujol, Roser
Hüneburg, Robert
Aretz, Stefan
Colas, Chrystelle
Villy, Marie-charlotte
R. Woodward, Emma
Gareth Evans, D.
G.m. Bosch, Daniëlle
H. Donze, Stephany
Foretová, Lenka
Blatnik, Ana
M. Leter, Edward
Tischkowitz, Marc
Jahn, Arne
De Putter, Robin
Dupont, Juliette
Briskemyr, Siri
Steinke-lange, Verena
Baldassarri, Margherita
C. Anastasiadou, Violetta
Irmejs, Arvīds
Oliveira, Carla
S. Van Der Post, Rachel
R. Mensenkamp, Arjen
Tesi, Bianca
Mu, Ninni
R. Benusiglio, Patrick
Gerasimenko, Anna
Innella, Giovanni
Turchetti, Daniela
Houdayer, Claude
Branchaud, Maud
Høberg Vetti, Hildegunn
Tveit Haavind, Marianne
Balmaña, Judith
Torres, Maite
Genuardi, Maurizio
Panfili, Arianna
Jørgensen, Kjersti
Mæhle, Lovise
Hoogerbrugge, Nicoline
R. Vos, Janet
Issue Date: 24-May-2025
Publisher: Elsevier BV
Abstract: Purpose: Patients with PTEN Hamartoma Tumor Syndrome (PHTS) have high hereditary cancer risks for breast, endometrial, and thyroid cancer. Patients develop multiple primary cancers, but these risks remain uncertain. We aimed to provide the second primary cancer risk. Methods: This European cohort study assessed second primary cancer risks with Kaplan-Meier analyses using data from medical files, registries and/or patient questionnaires. Results: Overall, 279 adult PHTS patients with (a history of) cancer were included (80% female). Among females, 106(54%) developed a PHTS-related second primary cancer after a PHTS-related first primary cancer, whereas 10 (29%) males developed a PHTS-related second primary cancer after a PHTS-related first primary cancer. The 5- and 10-year PHTS-related second primary cancer risks were 24.5% (95% CI = 18.1-32.5) and 45.7% (95% CI = 36.9-55.4) in females and 14.5% (95% CI = 5.7-34.1) and 19.8% (95% CI = 8.6-41.9) in males, respectively. Furthermore, 5- and 10-year risks for a second primary breast cancer after a first primary breast cancer were 23.3% (95% CI = 14.9-35.2) and 45.6% (95% CI = 33.0-60.2) in females, respectively. Conclusion: This study demonstrated that PHTS patients have high second primary cancer risks, which is driven by breast cancer in females. Hence, identifying patients with PHTS before or at first primary cancer diagnosis is essential to enable potential early detection or prevention of a second primary cancer through surveillance or risk-reducing surgery. (c) 2025 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.gim.2025.101467
It is part of: Genetics in Medicine, 2025, vol. 27, issue. 10, p. 101467
URI: https://hdl.handle.net/2445/223521
Related resource: https://doi.org/10.1016/j.gim.2025.101467
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PIIS1098360025001145.pdf704.15 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.